BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27807078)

  • 1. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
    Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
    Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and recognition of early esophageal neoplasia.
    Herszényi L; Pregun I; Tulassay Z
    Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma.
    Oberg S; Wenner J; Johansson J; Walther B; Willén R
    Ann Surg; 2005 Jul; 242(1):49-54. PubMed ID: 15973101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
    Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
    Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
    Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic therapy of esophageal premalignancy and early malignancy.
    Nealis TB; Washington K; Keswani RN
    J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett Esophagus.
    Iyer PG; Kaul V
    Mayo Clin Proc; 2019 Sep; 94(9):1888-1901. PubMed ID: 31486383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
    Becker L; Huang Q; Mashimo H
    Dis Esophagus; 2010 Feb; 23(2):168-74. PubMed ID: 19549212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice?
    Spechler SJ
    Ann Intern Med; 1987 Jun; 106(6):902-4. PubMed ID: 3579075
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical characteristics of young patients with early Barrett's neoplasia.
    Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
    World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.